Analysts Set TG Therapeutics, Inc. (NASDAQ:TGTX) Price Target at $26.17

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been given an average rating of “Moderate Buy” by the five ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $26.60.

TGTX has been the topic of several analyst reports. The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Thursday, February 29th. StockNews.com lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. B. Riley upped their price target on shares of TG Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday, February 5th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price objective on shares of TG Therapeutics in a report on Wednesday, February 28th.

TG Therapeutics Price Performance

TGTX opened at $14.00 on Friday. The stock’s 50-day moving average price is $15.15 and its 200 day moving average price is $13.87. The company has a current ratio of 5.92, a quick ratio of 5.18 and a debt-to-equity ratio of 0.62. TG Therapeutics has a 12-month low of $6.46 and a 12-month high of $35.67. The firm has a market cap of $2.16 billion, a price-to-earnings ratio of 700.35 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.03. The company had revenue of $43.97 million for the quarter, compared to analyst estimates of $40.06 million. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. During the same quarter in the previous year, the company posted ($0.39) earnings per share. As a group, sell-side analysts expect that TG Therapeutics will post -0.12 earnings per share for the current year.

Insider Buying and Selling at TG Therapeutics

In other news, Director Laurence N. Charney sold 22,000 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the transaction, the director now owns 215,229 shares of the company’s stock, valued at $3,437,207.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Pingora Partners LLC bought a new stake in shares of TG Therapeutics during the 4th quarter valued at about $27,000. Coppell Advisory Solutions LLC bought a new stake in shares of TG Therapeutics during the 2nd quarter valued at $46,000. Providence Capital Advisors LLC increased its stake in shares of TG Therapeutics by 1,403.9% during the first quarter. Providence Capital Advisors LLC now owns 1,910 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 1,783 shares in the last quarter. KBC Group NV purchased a new position in shares of TG Therapeutics in the 4th quarter worth about $54,000. Finally, PNC Financial Services Group Inc. grew its holdings in shares of TG Therapeutics by 131.7% during the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,014 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.